Can Colchicine Be Given During Acute Infection?
Colchicine should generally be avoided during active acute infections, with the specific exception being IL-1 blocker therapy, where current infection is an absolute contraindication, not colchicine itself.
Key Contraindications from Guidelines
The evidence regarding colchicine use during acute infection requires careful interpretation:
Absolute Contraindication Context
The 2016 EULAR guidelines explicitly state that "current infection is a contraindication to the use of IL-1 blockers" 1, not to colchicine itself. This is a critical distinction - the guideline is discussing when NOT to use IL-1 blockers (like anakinra) for gout flares, specifically mentioning that active infection precludes IL-1 blocker use, which would then necessitate considering colchicine as an alternative.
Drug Interactions During Infection
The more relevant safety concern is that colchicine should not be given to patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin 1. This is particularly important during acute infections when antibiotics like clarithromycin (a macrolide commonly used for respiratory infections) might be prescribed. The combination can lead to dangerous colchicine toxicity.
Clinical Decision Algorithm
When evaluating colchicine use in a patient with concurrent acute infection:
First, identify the type of infection and current medications:
- Is the patient on macrolide antibiotics (clarithromycin, erythromycin)?
- Is the patient on azole antifungals or other strong CYP3A4 inhibitors?
- If YES → Absolute contraindication to colchicine
Assess organ function:
Consider the indication:
- For acute gout flare during infection: Corticosteroids may be safer first-line option 3
- For FMF prophylaxis: Continue colchicine unless drug interactions present
- For gout prophylaxis: Generally continue unless severe infection with organ dysfunction
Evidence from COVID-19 Studies
Interestingly, colchicine has been studied extensively during acute SARS-CoV-2 infection with demonstrated safety and potential benefit 4, 5. One case-control study showed lower mortality (49.1% vs 72.9%, P=0.002) and lower intubation rates (52.8% vs 73.6%, P=0.006) in COVID-19 patients receiving colchicine 4. This suggests that in viral infections without contraindicated drug interactions, colchicine may actually be beneficial due to its anti-inflammatory properties.
Critical Caveats
The main concern is not infection per se, but rather:
- Drug-drug interactions with antimicrobials commonly used during infections (especially macrolides and azoles)
- Immunosuppression concerns are theoretical but not well-documented in clinical practice at standard doses
- Gastrointestinal side effects (diarrhea, nausea) may worsen during acute illness 3, 2
Practical Pitfall to Avoid
Do not confuse the EULAR statement about IL-1 blockers with a contraindication for colchicine. The guideline specifically states current infection contraindicates IL-1 blockers (biologics that cause significant immunosuppression), not colchicine. In fact, when IL-1 blockers cannot be used due to infection, colchicine becomes a more important alternative 1.
Bottom Line Recommendation
Colchicine can be given during acute infection UNLESS:
- Patient is taking strong CYP3A4/P-glycoprotein inhibitors (clarithromycin, cyclosporin, etc.)
- Patient has severe renal or hepatic impairment requiring dose adjustment
- The infection is severe enough to cause organ dysfunction that would impair colchicine clearance
For acute gout flares during infection, consider corticosteroids as first-line therapy 3, as they are generally safer and avoid potential drug interactions with antimicrobials.